Fatima Eltyeb Hago: Are We Doing More Harm Than Good with Combination Antithrombotic Therapy in AF?
Fatima Eltyeb Hago, Clinical Pharmacist at Dr. Sulaiman AL Habib Medical Group, shared on LinkedIn:
”Are we doing more harm than good with combination antithrombotic therapy in our AF patients?
In anticoagulated patients with atrial fibrillation, antiplatelet therapy should be the exception not the rule.
41% reduction in major bleeding with OAC alone vs. combination therapy .
(Gargiulo et al., JACC 2026 – meta-analysis of 4 RCTs, 4,092 patients)
45% of APT users in post-acute long-term care settings have no clear indication .
(Ko et al., JAMA Internal Medicine 2024)
Yet aspirin and P2Y12 inhibitors continue to be prescribed alongside anticoagulation with no reassessment, no stop dates, and no clear rationale.
This 2026 guide from the Anticoagulation Forum gives us the framework to act , verify the indication, assess the timing, and make a clear clinical decision: (deprescribe, monitor, or continue) with a defined plan.”
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025
-
Jun 23, 2026, 22:03Erin VanDyke: A Journey Through VTE Leadership and Healthcare Transformation
-
Jun 23, 2026, 21:19Ahmed Koriesh: Join Us for Future of Stroke Care 2026
-
Jun 23, 2026, 20:30Aladdin Mohammad: Baseline IgG as a Key Predictor of Hypogammaglobulinaemia in AAV